Gilteritinib has demonstrated robust FLT3 inhibition in human AML cell lines and induced strong antileukemic responses in FLT3-ITD+ patients with relapsed/refractory AML when administered as a single agent [21]. Here, FLT3 is linked to acute myeloid leukemia.